Scott Tagawa, MD, MS, FACP

GU Oncology Now

<p>Scott Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian &ndash; Weill Cornell Medical Center, highlights what clinicians must know prior to recommending Lutetium-177&ndash;PSMA-617 to patients, and whether there is a clinical cut-off for when patients would or wouldn&rsquo;t be considered.<p>View Dr. Tagawa&rsquo;s other comments on prostate cancer management, including <a href="https://guoncologynow.com/post/psma-pet-versus-cross-sectional-imaging" target="_blank" rel="noopener">PSMA PET Versus Cross-Sectional Imaging</a>&nbsp;and <a href="https://guoncologynow.com/post/rlt-administration-in-the-community-setting" target="_blank" rel="noopener">RLT Administration in the Community Setting</a>.</p></p>


Lutetium-177–PSMA-617: Appropriate and Potential Off-Label Utility

Radioligand therapy prostate-specific membrane antigen

Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe